Leriche L - Search Results

1

The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade.

Leriche L, Schwartz JC, Sokoloff P. Leriche L, et al. Neuropharmacology. 2003 Aug;45(2):174-81. doi: 10.1016/s0028-3908(03)00145-x. Neuropharmacology. 2003. PMID: 12842123

2

Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function.

Bézard E, Ferry S, Mach U, Stark H, Leriche L, Boraud T, Gross C, Sokoloff P. Bézard E, et al. Among authors: leriche l. Nat Med. 2003 Jun;9(6):762-7. doi: 10.1038/nm875. Epub 2003 May 12. Nat Med. 2003. PMID: 12740572

3

Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson's disease.

Guillin O, Griffon N, Bezard E, Leriche L, Diaz J, Gross C, Sokoloff P. Guillin O, et al. Among authors: leriche l. Eur J Pharmacol. 2003 Nov 7;480(1-3):89-95. doi: 10.1016/j.ejphar.2003.08.096. Eur J Pharmacol. 2003. PMID: 14623353 Review.

4

Dopamine D3 receptor ligands modulate the acquisition of morphine-conditioned place preference.

Francès H, Smirnova M, Leriche L, Sokoloff P. Francès H, et al. Among authors: leriche l. Psychopharmacology (Berl). 2004 Sep;175(2):127-33. doi: 10.1007/s00213-004-1807-9. Epub 2004 Apr 17. Psychopharmacology (Berl). 2004. PMID: 15095031

5

Dopamine and glutamate dysfunctions in schizophrenia: role of the dopamine D3 receptor.

Leriche L, Diaz J, Sokoloff P. Leriche L, et al. Neurotox Res. 2004;6(1):63-71. doi: 10.1007/BF03033298. Neurotox Res. 2004. PMID: 15184107 Review.

6

Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.

Guigoni C, Aubert I, Li Q, Gurevich VV, Benovic JL, Ferry S, Mach U, Stark H, Leriche L, Håkansson K, Bioulac BH, Gross CE, Sokoloff P, Fisone G, Gurevich EV, Bloch B, Bezard E. Guigoni C, et al. Among authors: leriche l. Parkinsonism Relat Disord. 2005 Jun;11 Suppl 1:S25-9. doi: 10.1016/j.parkreldis.2004.11.005. Parkinsonism Relat Disord. 2005. PMID: 15885624 Review.

7

The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders.

Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, Gross C. Sokoloff P, et al. Among authors: leriche l. CNS Neurol Disord Drug Targets. 2006 Feb;5(1):25-43. doi: 10.2174/187152706784111551. CNS Neurol Disord Drug Targets. 2006. PMID: 16613552 Review.

8

[Drugs acting on D3 receptors in neuropsychiatric disorders: facts and prospects. Implication for schizophrenia and its treatment in the regulation of BDNF-dependence on D3 receptor expression].

Sokoloff P, Leriche L. Sokoloff P, et al. Among authors: leriche l. Encephale. 2007 Nov;33(Pt 3):870-2. doi: 10.1016/s0013-7006(07)92912-7. Encephale. 2007. PMID: 18402360 Review. French. No abstract available.

9

Direct and indirect interactions of the dopamine D₃ receptor with glutamate pathways: implications for the treatment of schizophrenia.

Sokoloff P, Leriche L, Diaz J, Louvel J, Pumain R. Sokoloff P, et al. Among authors: leriche l. Naunyn Schmiedebergs Arch Pharmacol. 2013 Feb;386(2):107-24. doi: 10.1007/s00210-012-0797-0. Epub 2012 Sep 22. Naunyn Schmiedebergs Arch Pharmacol. 2013. PMID: 23001156 Free PMC article.

10

Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy.

Leriche L, Björklund T, Breysse N, Besret L, Grégoire MC, Carlsson T, Dollé F, Mandel RJ, Déglon N, Hantraye P, Kirik D. Leriche L, et al. J Neurosci. 2009 Feb 4;29(5):1544-53. doi: 10.1523/JNEUROSCI.4491-08.2009. J Neurosci. 2009. PMID: 19193901 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results